

CLAIMS

1. The use of an extract from plant material of the species *Trichilia* sp., wherein it is used for the combat, reversion and/or prevention of ventricular fibrillation.

5 2. The use according to claim 1, wherein the plant material is *Trichilia catigua* A. Juss.

 3. The use according to claim 1 or 2, wherein the plant material is *Trichilia catigua* A. Juss and it is in association with an extract of *Paullinia cupana* (Sapindaceae), *Croton moritibensis* (Euphorbiaceae) and *Zingiber officinale* (Zingiberaceae).

 4. The use according to claim 1, 2 or 3, wherein the extract is in the form of a product or pharmaceutical composition particularly having the following composition:

Liquid formulation:		
Component	% (m/v)	
	Generic	Preferred
Extract of <i>Trichilia</i> sp. (specially <i>Trichilia catigua</i> A. Juss)	0.50 to 10.0	0.50 to 5.00
Extract of <i>Paullinia cupana</i>	0.10 to 7.50	0.1 to 5.00
Extract of <i>Croton moritibensis</i>	0.01 to 5.50	0.01 to 5.0
Extract of <i>Zingiber officinale</i>	0.10 to 2.00	0.1 to 0.40
Suitable excipient	79.50 to 99.29	84.60 to 99.24

Solid formulation:		
Component	% (m/m)	
	Generic	Preferred
Extract of <i>Trichilia</i> sp. (specially <i>Trichilia catigua</i> A. Juss)	5 to 100	30 to 50
Extract of <i>Paullinia cupana</i>	2 to 30	10 to 21
Extract of <i>Croton moritibensis</i>	0.2 to 15.0	5 to 12
Extract of <i>Zingiber officinale</i>	0.5 to 3.0	0.5 to 1.5
Suitable excipient	2 to 92.30	15.5 to 54.5

15 5. The use according to claim 4, wherein the product or pharma-

ceutical composition in its dry and excipient-free form has the following composition:

Formulation		
Component	% (m/m)	
	Generic	Preferred
Extract of <i>Trichilia</i> sp. (specially <i>Trichilia catigua</i> A. Juss)	17 to 100	22 to 34
Extract of <i>Paullinia cupana</i>	24 to 57	32 to 48
Extract of <i>Croton moritibensis</i>	17 to 40	22 to 34
Extract of <i>Zingiber officinale</i>	2 to 5	2.5 to 4.0

6. The use according to any of claims 1 to 3, wherein said use is for the combat/reversion of spontaneous and electrical stimulus-induced ventricular fibrillation.

7. The use according to claim 6, wherein said use is for the reversion of spontaneous and electrical stimulus-induced ventricular fibrillation.

8. The use according to any of claims 1 to 7, wherein said use is for the prevention of ventricular fibrillation.

9. The use according to any of claims 1 to 7, wherein said use is for the treatment of ventricular fibrillation of any etiology.

10. The use according to any of claims 1 to 7, wherein said use is for post-fibrillation treatment in order to maintain regular cardiac rhythm.

11. A pharmaceutical composition, wherein said composition comprises plant material of the species *Trichilia* sp., alone or not in association with an extract of one or more of the following plants: *Paullinia cupana* (Sapindaceae), *Croton moritibensis* (Euphorbiaceae) and *Zingiber officinale* (Zingiberaceae) for combating/reverting spontaneous and electrical stimulus-induced ventricular fibrillation.

12. Pharmaceutical composition according to claim 11, wherein said pharmaceutical composition has the composition as defined in any of claims 4 or 5.

13. Pharmaceutical composition according to claim 11, wherein the plant material is *Trichilia catigua* A. Juss., alone or in said association, for

the reversion of spontaneous and electrical stimulus-induced ventricular fibrillation.

14. Pharmaceutical composition according to any of claims 11 to 13, wherein it is used for the treatment and/or prevention of any of the pathologies as defined in claims 6 to 10.

15. A method for reverting/combating ventricular fibrillation, wherein said method comprises the administration of a product or extract comprising plant material of the species *Trichilia* sp. to a patient in need thereof.

16. A method for reverting ventricular fibrillation according to claim 16, wherein the plant material is *Trichilia catigua* A. Juss.

17. The method for reverting/combating ventricular fibrillation according to claim 15, wherein said product has a composition as defined in any of claims 4 or 5.

18. The method of treatment and/or prevention according to any of claims 15 to 17, wherein said method is for the treatment and/or prevention of any pathologies as described in claims 6 to 10.

19. A use of a product comprising plant material of the species *Trichilia* sp., alone or in association with an extract of one or more of the following plants: *Paullinia cupana* (Sapindaceae), *Croton moritibensis* (Euphorbiaceae) and *Zingiber officinale* (Zingiberaceae), wherein it is used for preparing a pharmaceutical composition for reverting, combating and/or preventing ventricular fibrillation.

20. The use according to claim 19, wherein the plant material is *Trichilia catigua* A. Juss and it is used for the reversion of ventricular fibrillation.

21. The use according to claim 19, wherein said product has the composition as defined in any of claims 4 or 5.

22. The use according to claim 19 or 21, wherein the product is used for the reversion of ventricular fibrillation as described in claims 6 to 10.